See the Entire Portfolio

Iterative Scopes

B2B Current Investment

Iterative Scopes is pioneering the application of precision medicine to gastroenterology with the aim of enhancing colorectal cancer screenings. The technology is also designed to help optimize clinical trials investigating treatment of inflammatory bowel disease. Its powerful, proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to improve polyp detection for colorectal cancer screenings and standardizing disease severity characterization for inflammatory bowel disease (IBD). Longer term, the company plans to establish more meaningful endpoints for GI diseases, which can be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Massachusetts.

News from Iterative Scopes: